Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 200 Results

Title
Intervention Indication Therapeutic Area Year Actions
Ustekinumab biosimilar for treating moderate to severe plaque psoriasis Ustekinumab biosimilar (ONS3040; FYB202; CT-P43; BAT2206; DMB-3115; SB17; Bmab 1200; AVT04; ABP654) Plaque psoriasis Dermatology 2022 View  |  Download
Vedolizumab for treating active pouchitis Vedolizumab (Entyvio; LDP-02; MLN0002) Pouchitis Gastroenterology 2022 View  |  Download
Vutrisiran for treating hereditary transthyretin amyloidosis Vutrisiran (ALN-TTRSC02) Amyloidosis Endocrine Nutritional and Metabolic Disorders 2022 View  |  Download
Xevinapant with platinum-based chemoradiotherapy for previously untreated locally advanced squamous cell carcinoma of the head and neck Xevinapant (Debio 1143; AT-406) Head and neck cancer Head and Neck Cancer 2022 View  |  Download
Zamtocabtagene autoleucel for relapsed or refractory diffuse large B-cell lymphoma after at least 2 therapies Zamtocabtagene autoleucel Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma Zamtocabtagene autoleucel Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zanubrutinib for previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma Zanubrutinib (BGB-3111; Brukinsa) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zanubrutinib for relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma Zanubrutinib (BGB-3111; Brukinsa) Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zanubrutinib for treating marginal zone lymphoma Zanubrutinib (BGB-3111; Brukinsa) Marginal zone lymphoma (MZL) Haematological Cancer and Lymphomas 2022 View  |  Download
Zolbetuximab for previously untreated advanced gastric or gastro-oesophageal junction adenocarcinoma Zolbetuximab (IMAB362) Gastro-oesophageal junction cancer Gastrointestinal Cancer 2022 View  |  Download
1 2 18 19 20
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications